Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Ocrelizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Polpharma, MS Pharma Ink Licensing Agreements for Biosimilars
    Polpharma, MS Pharma Ink Licensing Agreements for Biosimilars

    02 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250902492755/en/Polpharma-Biologics-and-MS-Pharma-Sign-Licensing-Agreements-for-Proposed-Vedolizumab-PB016-Ocrelizumab-PB018-and-Guselkumab-PB019-Biosimilars

    BUSINESSWIRE
    02 Sep 2025
    Share Share
    Genentech’s Biologic Ocrevus Zunovo Receives Suppl Approval in US
    Genentech’s Biologic Ocrevus Zunovo Receives Suppl Approval in US

    18 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761371

    FDA
    18 Aug 2025
    Share Share
    Roche's high-dose version of Ocrevus flunks phase 3 trial
    Roche's high-dose version of Ocrevus flunks phase 3 trial

    03 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biosimilar-competition-looming-roche-takes-hit-failure-high-dose-ocrevus

    FIERCE PHARMA
    03 Apr 2025
    Share Share
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402207576/en/Genentech-Provides-Update-on-Phase-III-Ocrevus-High-Dose-Study-in-People-With-Relapsing-Multiple-Sclerosis

    BUSINESSWIRE
    02 Apr 2025
    Share Share
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US

    13 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761371

    FDA
    13 Sep 2024
    Share Share
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share